Treatment of endometriosis with the GnRH agonist nafarelin acetate.
article
OA: closed
CC0
⤵ 5 in-corpus citations
AI-generated summary
This review details a multicenter study of nafarelin acetate for endometriosis, including its scoring system and symptom relapse after treatment with nafarelin and danazol.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Additional details of a multicenter study of nafarelin acetate with particular attention to a unique endometriosis scoring system utilized are reviewed. Additional information regarding the relapse of symptoms of 10 patients treated with nafarelin and danazol during a 6- to 12-month follow-up interval is described. Transient decreases in leukocytes previously reported by other investigators were observed in 3 of 8 patients, but appear to represent a laboratory artifact.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (5)
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 2010
- Ovulation suppression for endometriosis for women with subfertility 2007
- Ovulation suppression for endometriosis 2003
- The use of GnRH agonists in the treatment of endometriomas with or without drainage. 1996
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:12:05.481982+00:00
License: CC0
· commercial use OK